Literature DB >> 21476143

Infectious disease screening of blood specimens collected post-mortem provides comparable results to pre-mortem specimens.

Cristina Baleriola1, Harpreet Johal, Peter Robertson, Brendan Jacka, Ross Whybin, Peter Taylor, William D Rawlinson.   

Abstract

Serology assays for standard screening are optimised for use with sera collected from living adults and children. Because of potential changes in the vascular compartments after death, methods used for screening sera from cadaveric organ donors need to be validated before testing these specimens. Serum was separated from blood collected from cadaveric donors within 24 h of death and biochemical parameters measured to detect dilution of protein and haemolysis. In order to demonstrate if any inhibitors that might interfere with the assays were present, pre and post-mortem specimens were spiked with aliquots of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-cell Lymphotropic Virus (HTLV) and T. pallidum-positive sera. Comparison of serum from living subjects with serum obtained post-mortem showed that while the concentration of total protein decreased, concentrations of albumin, immunoglobulin G (IgG) and immunoglobulin M (IgM) remained unchanged. The degree of haemolysis, as measured by free haemoglobin, was within the limits accepted for the Architect analyser. Spiking of pre- and post-mortem specimens with aliquots of HIV, HCV, HBV, HTLV and T. pallidum-positive sera showed no statistical difference in the signal between pre-mortem and post-mortem results when tested on the Abbott Architect analyser. Positive results were obtained in each of a further nine subjects who had tested positive for HIV (n=1), HCV (n=8), HBV (n=1) on pre-mortem serological testing. These findings suggest that the sensitivity of the Abbott Architect serological screening tests is not significantly affected in specimens collected within 24 h of the cessation of life.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21476143     DOI: 10.1007/s10561-011-9252-6

Source DB:  PubMed          Journal:  Cell Tissue Bank        ISSN: 1389-9333            Impact factor:   1.522


  5 in total

1.  Cost savings associated with testing of antibodies, antigens, and nucleic acids for diagnosis of acute HIV infection.

Authors:  Maile Y Karris; Christy M Anderson; Sheldon R Morris; Davey M Smith; Susan J Little
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

2.  Validation of OraQuick HCV Rapid Antibody Test in Postmortem Specimens.

Authors:  Claire E Rose; Lisa Duncan; Amy M Hawes
Journal:  Acad Forensic Pathol       Date:  2020-11-25

Review 3.  Hepatitis B transmission by cell and tissue allografts: how safe is safe enough?

Authors:  Pilar Solves; Vicente Mirabet; Manuel Alvarez
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

4.  Validation of Spiked Postmortem Blood Samples from Cornea Donors on the Abbott ARCHITECT and m2000 Systems for Viral Infections.

Authors:  Ingo Schmack; Seda Ballikaya; Brigitte Erber; Irina Voehringer; Ulrich Burkhardt; Gerd U Auffarth; Paul Schnitzler
Journal:  Transfus Med Hemother       Date:  2019-09-24       Impact factor: 3.747

5.  Serological testing on the ADVIA Centaur system for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in specimens from deceased and living individuals demonstrates equivalent resultsƚ.

Authors:  Theodore B Wright; Sai Patibandla; Renee Walsh; Rachel Fonstad; Matthew Gee; Vera Bitcon; Julie Hopper; Susie J Braniff; Susan Best; Scott Read
Journal:  Transpl Infect Dis       Date:  2022-03-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.